Hiraoka Atsushi, Kume Misaki, Miyagawa Masao, Tazuya Nayu, Ichiryu Misa, Ochi Hironori, Tanabe Atsushi, Nakahara Hiromasa, Shinbata Yuki, Kan Miki, Doi Shigekazu, Hidaka Satoshi, Uehara Takahide, Tanihira Tetsuya, Hasebe Aki, Miyamoto Yasunao, Ninomiya Tomoyuki, Hirooka Masashi, Abe Masanori, Hiasa Yoichi, Matsuura Bunzo, Onji Morikazu, Michitaka Kojiro
Gastroenterology Center, Ehime Prefectural Central Hospital, Ehime, Japan.
Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1237-40.
BACKGROUND/AIMS: This study was conducted to evaluate the diagnostic efficacy of contrast enhanced ultrasonography (CEUS) with perflubutane (Sonazoid) for hepatic metastasis and compared it with that of 18-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT).
From January 2007 to July 2009, 109 Japanese patients with gastrointestinal tract cancer were enrolled, of whom 4 had esophageal cancer, 28 gastric cancer, 1 duodenal cancer, and 76 colorectal cancer. After a bolus injection with Sonazoid (0.5 ml/body), the liver was scanned in both arterial and Kupffer phases. The results of PET/CT and other abdominal imaging examinations were not shown to the CEUS operators. We compared diagnostic efficacy between CEUS and PET/CT.
Average values for age, body mass index, and maximum diameter of the hepatic metastasis were 68.7 +/- 11.0 years, 21.2 +/- 4.2, and 29.2 +/- 20.5mm, respectively. Hepatic metastasis were suspected in 31 patients based on PET/CT findings and 32 by CEUS. Finally, hepatic metastasis was diagnosed in 30 patients. The sensitivity, specificity, and accuracy rates for CEUS and PET/CT were similar (100% vs. 100%, 97.5% vs. 98.7%, and 95.5% vs. 93.6%, respectively).
CEUS had a diagnostic value similar to that of PET/CT for hepatic metastasis.
Zotero 插件